Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
MEDPLUS
Dr. Gangadi Madhukar Reddy · Hyderabad, India · 28,872 employees
₹721.00
▲+2.90%MEDPLUS is trading near its 52-week low after a significant pullback from its highs, despite strong revenue growth and analyst consensus, suggesting potential value recovery opportunity.
Exchange
NSI
Currency
INR
Day range
₹697.60 – ₹725.00
52-week range
₹653.00 – ₹1,022.20
Sector
Healthcare
Industry
Pharmaceutical Retailers
AI investment rating
AI analysis75% confidence
The stock appears undervalued relative to its 52-week range and strong revenue growth, though the high P/E ratio suggests premium valuation that needs justification through sustained earnings growth.
29.5% below the 1-year high · trend up
Hedge-fund memo
Today
The stock is up 2.90% today, trading in the lower third of its 52-week range with moderate volume.
This week
The stock has shown some recovery after recent weakness, testing resistance around 725 INR.
This month
Over the past month, MEDPLUS has declined significantly from higher levels, presenting a potential entry point for long-term investors.
Bull thesis
Bear thesis
News & sentiment
Neutral
24 headlines · 11 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 4 of 4 recent quarters (EPS actual vs. consensus).
2.76 vs 1.95
41.54% surprise
5.33 vs 5.15
3.50% surprise
4.81 vs 4.53333
6.10% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| MEDPLUS | 171.74B | 40.80 | — | 2.94% | 21.80% |
| VIJAYA | 140.10B | 81.25 | 19.70% | 32.45% | 26.60% |
| SAPPHIRE | 62.82B | — | — |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 498sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Intense competition from organized and unorganized retail players
Mitigation: Continue focusing on operational efficiency and customer experience
Regulatory changes in pharmaceutical distribution
Mitigation: Maintain compliance and adapt business model as needed
Business intelligence
Competitive moat
Extensive retail network and strong brand recognition provide significant scale advantages and bargaining power with suppliers.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Continued store expansion and market share gains
Potential margin improvement initiatives
Thesis builder
Bull case
The company's leading position in India's growing pharmacy retail sector with strong revenue growth drives significant upside potential.
Base case
Moderate growth as the company expands its store network while maintaining profitability in a competitive market.
Bear case
Margin pressure and high valuation could lead to underperformance if growth slows.
Time horizon
18-24 months
Est. CAGR
15-20%
Entry (qual.)
Current levels near 52-week low provide attractive entry point for long-term investors.
Exit (qual.)
Consider reducing position if stock approaches 52-week high without corresponding earnings growth justification.
Overall conviction 75%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how MEDPLUS fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain MEDPLUS for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden risks
Hidden opportunities
Watch next
Given the strong revenue growth and current valuation levels, MEDPLUS presents a compelling long-term investment opportunity despite near-term volatility.
scanx.trade·2d ago·share pledge signals promoter stress
Whalesbook·2d ago·share pledge signals promoter stress
Whalesbook·2d ago·share pledge signals promoter stress
TradingView·2d ago·irrelevant to company outlook
scanx.trade·3d ago·regulatory suspension impacts operations
TipRanks·4d ago·regulatory suspension impacts operations
scanx.trade·5d ago·ESG disclosure shows governance focus
Business Upturn·5d ago·profit surge indicates strong growth
Whalesbook·6d ago·MF stake increase signals confidence
The Economic Times·6d ago·irrelevant to company outlook
simplywall.st·6d ago·target cut signals analyst concern
Whalesbook·7d ago·profit growth on revenue rise
Whalesbook·7d ago·profit growth on revenue rise
Whalesbook·7d ago·profit growth on revenue rise
Whalesbook·7d ago·profit growth on revenue rise
Business Standard·7d ago·capex pause signals growth concern
CNBC TV18·7d ago·analyst cautious on stock
TipRanks·7d ago·capex pause signals growth concern
Investing.com Nigeria·7d ago·margin pressure offsets revenue
scanx.trade·7d ago·profit falls despite revenue rise
scanx.trade·7d ago·capex pause signals growth concern
TradingView·7d ago·capex pause signals growth concern
Whalesbook·7d ago·capex pause signals growth concern
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
4.62 vs 4.15
11.33% surprise
| 4.76% |
| 14.70% |
| STARHEALTH | 359.16B | 64.52 | — | 3.25% | 13.80% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹697.60
Resistance (day/52w high)
₹725.00
Volume
2,10,658
Trend
up
RSI (14)
29
MACD
bearish
MA cross
golden
50-day MA
₹831.32
200-day MA
₹829.20
vs 200-DMA
-13.0%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.